The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It works. It does what it's supposed to do, & that is improve the chemo by targeting the cancer. It's not a cure. The drug is the cure. Ava6000 allows many more doses with little toxicity. Ava3996 sounds even more promising. 'The Market' will, in the main, be ignorant about the tech, as I'm sure many Avacta investors are. So why should 'The Market' be knowledgeable? Those that will understand the tech will be the biotechs. Also, seems many 'investors' (on this bb at least) don't understand the trial process & purpose. So what chance has either 'Mr Market', or the media got?
Avacta will not reward understanding, but, it (likely) will patience.
The strategy doesn't sit with how Myles understood Avacta was/is going to progress at this time
"continues to actively pursue other opportunities that add the other pieces of the jigsaw to build a fully integrated diagnostics business".
He was under the impression our funds were to be focused on TX.
Prof, whoever predicted £2 had the excuse of using, & speculating, on what was/is known about Avacta organically.
Chartists use historical sp movement only & don't need to know any detail about their target. So when a technical 'expert' contributes, they have nothing to add, other than encourage some who wish to trade. Think majority on this bb take a longer view of the company.
Highlighted in our new COO's cv is Astellas, a Japanese coy with an extensive international presence.
So another senior management position filled by a person with experience at a senior level within a large corporate entity.
Oh well, I suppose another joining the ever growing list of freeloaders!
Maggie Pagano's article in the Daily Mail highlights the short-sightedness/shortcomings of domestic investors in the light of Softbank's decision to float Arm in New York. The recent Heights investment only underlines the problem. Seems likely the sp is suffering from 'risk-averse UK investors'.
Agree with PL, but don't think the silly funders have much effect. They are annoying & disruptive, but doubt they have much impact on the sp. Likely there was a least one big seller at play (again), maybe some shorted, those that are careful, inexperienced, ignorant of the science, or have set stop losses, sell. Be surprised if any (true) LTHs have unloaded. Those that can, will add.
Sure you know Timster, but those who plague this bb with 'woof woof' & similar sentiments have absolutely no interest in the science. The criterion is price (short term), nothing else. They will have their days, as LTHs will have theirs.